過敏性腸症候群（IBS）治療の世界市場レポート 2025年

過敏性腸症候群（IBS）治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.5％で49億3,000万米ドルに成長します。予測期間の成長は、患者中心のヘルスケアモデル、微生物療法、ヘルスケアにおけるブロックチェーン、患者報告アウトカム（pros）、規制のファストトラックプログラム、ヘルスデータの相互運用性に起因しています。予測期間の主な動向には、デジタルヘルスソリューションの統合、診断技術の進歩、研究開発投資の増加、共同研究やパートナーシップ、非薬物療法の出現などが含まれます。

過敏性腸症候群（IBS）治療市場の成長が期待されるのは、過敏性腸症候群（IBS）の有病率の増加です。IBSは大腸に影響を及ぼす慢性的な胃腸障害であり、その有病率の上昇は、生活習慣の悪化、不健康な食習慣、汚染への暴露、ストレスレベルの上昇などに起因しています。IBSの治療は、症状を和らげ、重症度と頻度を減らし、個人の状態を効果的に管理する能力を高めることを目的としています。国際胃腸障害財団（IFFGD）によると、2023年には世界人口の約5～10％がIBSに罹患し、米国では2,500万人から4,500万人が罹患すると予想されています。その結果、IBSの有病率の増加は、IBS治療市場の拡大を促す重要な要因となっています。

IBS治療市場の成長は高齢化によって促進されると予想されます。高齢化とは、社会における高齢者の割合の増加を特徴とする人口動向を指します。この層の人々は、加齢に伴う胃腸症状を管理するためにIBS治療を利用し、消化器系の健康における加齢に関連した変化に対処し、不快感を和らげ全体的な幸福をサポートすることで、より良い生活の質を促進します。世界保健機関（WHO）が2022年10月に報告したように、60歳以上の世界人口は急速に増加しており、2050年までに倍増して21億人に達すると予想されています。したがって、高齢化はIBS治療市場成長の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界過敏性腸症候群（IBS）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の過敏性腸症候群（IBS）治療市場：成長率分析
• 世界の過敏性腸症候群（IBS）治療市場の実績：規模と成長, 2019-2024
• 世界の過敏性腸症候群（IBS）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界過敏性腸症候群（IBS）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の過敏性腸症候群（IBS）治療市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ルビプロストン
• リナクロチド
• エルクサドリン
• リファキシミン
• アロセトロン
• その他の薬物
• 世界の過敏性腸症候群（IBS）治療市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 便秘を伴うIBS
• 下痢を伴うIBS
• 便秘と下痢を繰り返すIBS
• 世界の過敏性腸症候群（IBS）治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の過敏性腸症候群（IBS）治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア設定
• 世界の過敏性腸症候群（IBS）治療市場、ルビプロストンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性特発性便秘の治療
• 便秘を伴う過敏性腸症候群（IBS-C）の治療
• 世界の過敏性腸症候群（IBS）治療市場リナクロチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IBS-Cの治療
• 慢性特発性便秘の治療
• 世界の過敏性腸症候群（IBS）治療市場、エルクサドリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下痢を伴うIBS（IBS-D）の治療
• 世界の過敏性腸症候群（IBS）治療市場リファキシミンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• IBS-Dの治療
• 小腸細菌異常増殖症（SIBO）の治療
• 世界の過敏性腸症候群（IBS）治療市場、アロセトロンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 女性のための重度のIBS-D治療
• 世界の過敏性腸症候群（IBS）治療市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プルカロプリド
• テナパノール
• プレカナチド

第7章 地域別・国別分析

• 世界の過敏性腸症候群（IBS）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の過敏性腸症候群（IBS）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 過敏性腸症候群（IBS）治療市場：競合情勢
• 過敏性腸症候群（IBS）治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Ironwood Pharmaceuticals Inc.
• Sebela Pharmaceuticals Inc.
• Prometheus Laboratories Inc.
• RedHill Biopharma Ltd.
• Ardelyx Inc.
• Cosmo Technologies Ltd.
• Renexxion Ireland Ltd.
• 4D Pharma plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 過敏性腸症候群（IBS）治療市場2029：新たな機会を提供する国
• 過敏性腸症候群（IBS）治療市場2029：新たな機会を提供するセグメント
• 過敏性腸症候群（IBS）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for irritable bowel syndrome (IBS) involves a range of approaches and interventions directed at addressing disorders in the gastrointestinal tract, common issues that impact the stomach and intestines. The objective of IBS treatment is to alleviate symptoms such as constipation, diarrhea, and abdominal discomfort, reduce the frequency and severity of flare-ups, and enhance overall well-being.

The primary categories of drugs used in irritable bowel syndrome (IBS) treatment include lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. Lubiprostone, for instance, is a medication employed in treating IBS. It functions as a selective chloride channel activator, facilitating increased fluid secretion in the intestines. The drug is indicated for IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. These medications are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to diverse end-users such as hospitals, clinics, and home care settings.

The irritable bowel syndrome (IBS) treatment market research report is one of a series of new reports from The Business Research Company that provides irritable bowel syndrome (IBS) treatment market statistics, including irritable bowel syndrome (IBS) treatment industry global market size, regional shares, competitors with an irritable bowel syndrome (IBS) treatment market share, detailed irritable bowel syndrome (IBS) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the irritable bowel syndrome (IBS) treatment industry. This irritable bowel syndrome (IBS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The irritable bowel syndrome (IBS) treatment market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.07 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing prevalence of ibs, growing patient awareness, stress and lifestyle factors, patient advocacy and support groups, healthcare reimbursement policies

The irritable bowel syndrome (IBS) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to patient-centric healthcare models, microbial therapies, blockchain in healthcare, patient-reported outcomes (pros), regulatory fast-track programs, health data interoperability. Major trends in the forecast period include integration of digital health solutions, advancements in diagnostic technologies, increased research and development investments, collaborations and partnerships, emergence of non-pharmacological therapies.

The anticipated growth of the irritable bowel syndrome (IBS) treatment market is driven by the increasing prevalence of irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal disorder affecting the large intestine, and its rising prevalence is attributed to poor lifestyles, unhealthy eating habits, exposure to pollution, and heightened stress levels. Treatment for IBS aims to alleviate symptoms, reduce their severity and frequency, and enhance individuals' ability to manage their conditions effectively. According to the International Foundation for Gastrointestinal Disorders (IFFGD), approximately 5-10% of the global population is expected to have IBS in 2023, with between 25 and 45 million people in the United States affected by the condition. Consequently, the growing prevalence of IBS is a key factor driving the expansion of the IBS treatment market.

The growth of the IBS treatment market is expected to be propelled by the aging population. The aging population refers to a demographic trend characterized by an increasing proportion of elderly individuals within a society. Individuals in this demographic group utilize IBS treatment to manage gastrointestinal symptoms associated with aging, addressing age-related changes in digestive health and promoting a better quality of life by alleviating discomfort and supporting overall well-being. As reported in October 2022 by the World Health Organization (WHO), the global population of individuals aged 60 years and older is rapidly growing and is expected to double by 2050, reaching 2.1 billion. Hence, the aging population is a significant driver for the growth of the IBS treatment market.

A prominent trend in the irritable bowel syndrome (IBS) market is the focus on product innovations by major players. Leading companies in the IBS market are actively engaged in developing new and advanced products to reinforce their market positions. For instance, in April 2022, Ardelyx, a U.S.-based biotechnology company, introduced IBSRELA, a first-in-class treatment for IBS-C in adults. IBSRELA, the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C), offers a novel mechanism therapy for IBS-C and represents a significant new treatment option for constipation, bloating, and stomach pain associated with this debilitating disorder.

Major companies in the irritable bowel syndrome (IBS) market are adopting a strategic partnership approach to address conditions such as Crohn's disease and ulcerative colitis. Strategic partnerships involve collaboration between companies to leverage each other's strengths and resources for mutual benefits. In October 2023, Sanofi S.A., a France-based pharmaceutical industry company, formed a partnership with Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, aiming to provide treatment for inflammatory bowel disease.

In October 2023, Roche, a Switzerland-based healthcare company, acquired Telavant Holdings for an undisclosed amount. Through this acquisition, Roche gains the rights to develop, manufacture, and market a novel treatment for Irritable Bowel Syndrome (IBS) in the United States and Japan. Telavant Holdings, a U.S.-based biotechnology company, specializes in developing and commercializing innovative therapies for inflammatory and fibrotic diseases.

Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the irritable bowel syndrome (ibs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The irritable bowel syndrome (IBS) treatment market includes revenues earned by entities by providing services such as consultation, cognitive-behavioral therapy (CBT), hypnotherapy, psychological therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The irritable bowel syndrome (IBS) market also includes sales of antispasmodics, fiber supplements, laxatives, probiotics, and certain medications targeting gut function. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on irritable bowel syndrome (ibs) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for irritable bowel syndrome (ibs) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The irritable bowel syndrome (ibs) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
• 2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
• 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
• 4) By End-Users: Hospitals, Clinics, Homecare Settings
• Subsegments:
• 1) By Lubiprostone: Chronic Idiopathic Constipation Treatment; Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
• 2) By Linaclotide: IBS-C Treatment; Chronic Idiopathic Constipation Treatment
• 3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
• 4) By Rifaximin: IBS-D Treatment; Small Intestinal Bacterial Overgrowth (SIBO) Treatment
• 5) By Alosetron: Severe IBS-D Treatment for Women
• 6) By Other Drugs: Prucalopride; Tenapanor; Plecanatide
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Novartis AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Irritable Bowel Syndrome (IBS) Treatment Market Characteristics

3. Irritable Bowel Syndrome (IBS) Treatment Market Trends And Strategies

4. Irritable Bowel Syndrome (IBS) Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Irritable Bowel Syndrome (IBS) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Irritable Bowel Syndrome (IBS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Irritable Bowel Syndrome (IBS) Treatment Market Growth Rate Analysis
• 5.4. Global Irritable Bowel Syndrome (IBS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Irritable Bowel Syndrome (IBS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Irritable Bowel Syndrome (IBS) Treatment Total Addressable Market (TAM)

6. Irritable Bowel Syndrome (IBS) Treatment Market Segmentation

• 6.1. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lubiprostone
• Linaclotide
• Eluxadoline
• Rifaximin
• Alosetron
• Other Drugs
• 6.2. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IBS With Constipation
• IBS With Diarrhea
• IBS With Alternating Constipation And Diarrhea
• 6.3. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• 6.5. Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Lubiprostone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Idiopathic Constipation Treatment
• Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
• 6.6. Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Linaclotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IBS-C Treatment
• Chronic Idiopathic Constipation Treatment
• 6.7. Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Eluxadoline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IBS with Diarrhea (IBS-D) Treatment
• 6.8. Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Rifaximin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IBS-D Treatment
• Small Intestinal Bacterial Overgrowth (SIBO) Treatment
• 6.9. Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Alosetron, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe IBS-D Treatment for Women
• 6.10. Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prucalopride
• Tenapanor
• Plecanatide

7. Irritable Bowel Syndrome (IBS) Treatment Market Regional And Country Analysis

• 7.1. Global Irritable Bowel Syndrome (IBS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Irritable Bowel Syndrome (IBS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market

• 8.1. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Irritable Bowel Syndrome (IBS) Treatment Market

• 9.1. China Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 9.2. China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Irritable Bowel Syndrome (IBS) Treatment Market

• 10.1. India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Irritable Bowel Syndrome (IBS) Treatment Market

• 11.1. Japan Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 11.2. Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Irritable Bowel Syndrome (IBS) Treatment Market

• 12.1. Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market

• 13.1. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Irritable Bowel Syndrome (IBS) Treatment Market

• 14.1. South Korea Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 14.2. South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market

• 15.1. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 15.2. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Irritable Bowel Syndrome (IBS) Treatment Market

• 16.1. UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Irritable Bowel Syndrome (IBS) Treatment Market

• 17.1. Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Irritable Bowel Syndrome (IBS) Treatment Market

• 18.1. France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Irritable Bowel Syndrome (IBS) Treatment Market

• 19.1. Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Irritable Bowel Syndrome (IBS) Treatment Market

• 20.1. Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market

• 21.1. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 21.2. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Irritable Bowel Syndrome (IBS) Treatment Market

• 22.1. Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Irritable Bowel Syndrome (IBS) Treatment Market

• 23.1. North America Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 23.2. North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Irritable Bowel Syndrome (IBS) Treatment Market

• 24.1. USA Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 24.2. USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Irritable Bowel Syndrome (IBS) Treatment Market

• 25.1. Canada Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 25.2. Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Irritable Bowel Syndrome (IBS) Treatment Market

• 26.1. South America Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 26.2. South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Irritable Bowel Syndrome (IBS) Treatment Market

• 27.1. Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Irritable Bowel Syndrome (IBS) Treatment Market

• 28.1. Middle East Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 28.2. Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Irritable Bowel Syndrome (IBS) Treatment Market

• 29.1. Africa Irritable Bowel Syndrome (IBS) Treatment Market Overview
• 29.2. Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Irritable Bowel Syndrome (IBS) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Irritable Bowel Syndrome (IBS) Treatment Market Competitive Landscape
• 30.2. Irritable Bowel Syndrome (IBS) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Irritable Bowel Syndrome (IBS) Treatment Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Astellas Pharma Inc.
• 31.6. Biogen Inc.
• 31.7. Bausch Health Companies Inc.
• 31.8. Ironwood Pharmaceuticals Inc.
• 31.9. Sebela Pharmaceuticals Inc.
• 31.10. Prometheus Laboratories Inc.
• 31.11. RedHill Biopharma Ltd.
• 31.12. Ardelyx Inc.
• 31.13. Cosmo Technologies Ltd.
• 31.14. Renexxion Ireland Ltd.
• 31.15. 4D Pharma plc

32. Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market

34. Recent Developments In The Irritable Bowel Syndrome (IBS) Treatment Market

35. Irritable Bowel Syndrome (IBS) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Irritable Bowel Syndrome (IBS) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Irritable Bowel Syndrome (IBS) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Irritable Bowel Syndrome (IBS) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer